We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 276

China relaxes price regulation on 15 professional services including patent agency

  • China Patent Agent (HK) Ltd
  • -
  • China
  • -
  • July 17 2014

The National Development and Reform Commission of China (NDRC) recently announced the liberalisation of price regulation on 15 professional services

UK and China launch pilot Patent Prosecution Highway program

  • Shook Hardy & Bacon LLP
  • -
  • China, United Kingdom
  • -
  • July 17 2014

The United Kingdom and People's Republic of China have launched a pilot program that will allow applicants who have successfully obtained a patent in

The new China and your company's intellectual property

  • Baker Donelson Bearman Caldwell & Berkowitz PC
  • -
  • China
  • -
  • July 9 2014

The Chinese economy has changed dramatically in the past two, five, and even 20 years, but its intellectual property (IP) laws have only very

Decision of the Supreme People's Court on revising “Certain Provisions of the Supreme People's Court on Issues Concerning the Application of Law in the Hearing of Patent Dispute Cases” (Draft for Soliciting Public Opinion)

  • Beijing East IP Ltd
  • -
  • China
  • -
  • July 17 2014

On July 16, the Supreme People's Court published the Decision of the Supreme People's Court on Revising the "Certain Provisions of the Supreme

Patent term extensions and regulatory exclusivities for pharmaceuticals in Asia and South America

  • Morrison & Foerster LLP
  • -
  • Argentina, Brazil, Chile, China, Hong Kong, Japan, Malaysia, Mexico, Philippines, South Korea, Thailand, USA, Vietnam
  • -
  • June 27 2012

Patent protection for pharmaceutical products has an impact on the pharmaceutical market and innovation

Follow the yellow bit road?: JP Morgan pursues bitcoin-like patent

  • King & Wood Mallesons
  • -
  • China, European Union, USA
  • -
  • December 19 2013

Digital currencies are a hot topic these days, with their anonymity, freedom from control by centralised banks, and avoidance of merchant transaction

SPC invites public comments on draft amendments to judicial interpretation on application of law in trial of patent dispute cases

  • China Patent Agent (HK) Ltd
  • -
  • China
  • -
  • July 18 2014

The Supreme People's Court of China (SPC) published on 16 July 2014 the Decision on Amendments to Several Provisions of the Supreme People's Court of

Pharmaceutical compulsory licences in emerging markets: necessity or threat?

  • CMS Cameron McKenna
  • -
  • China, India
  • -
  • August 27 2013

A compulsory licence provides that the owner of a patent licenses the use of their rights in return for payment either set by law or determined

China’s Patent Re-Examination Board says pharmaceutical salts not patentable over pure compounds

  • Greenberg Traurig LLP
  • -
  • China
  • -
  • August 14 2013

In July 2013, the Patent Re-Examination Board of China's State Intellectual Property Office invalidated the U.S. biotech company, Gilead Sciences'

Overview of patent-statutory subject matter in biotechnology

  • CCPIT Patent & Trademark Law Office
  • -
  • China, European Union, Japan, USA
  • -
  • April 8 2013

With the advent of biotechnology, the human community stands on the threshold of an extraordinary revolution having profound